LINC00565 Enhances Proliferative Ability in Endometrial Carcinoma by Downregulating KLF9.
KLF9
LINC00565
endometrial carcinoma
proliferation
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
02
2020
accepted:
13
05
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
9
7
2020
Statut:
epublish
Résumé
To detect LINC00565 expression level in endometrial carcinoma (EC) samples and cell lines, and the correlations between LINC00565 and clinical features of EC patients. After intervening LINC00565, the underlying mechanism about proliferative ability in EC cell lines is observed. Relative levels of LINC00565 and KLF9 in 52 paired EC and paracancerous tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The relationship between relative level of LINC00565 or KLF9 and clinical features of EC patients was analyzed. After knockdown of LINC00565 and KLF9, potential regulations of them on biological functions of EC were examined by Cell Counting Kit (CCK-8), colony formation assay and in vivo xenograft model in nude mice, respectively. At last, dual-luciferase reporter assay and rescue experiments were conducted to illustrate the mechanisms of LINC00565 and KLF9 in mediating the development of EC. LINC00565 was upregulated in EC tissues. Chi-square analysis showed that a high level of LINC00565 predicted large tumor size, advanced pathological staging and poor prognosis in EC. Silence of LINC00565 decreased proliferative ability in EC cells and tumor growth in nude mice bearing EC. KLF9 was the target gene of LINC00565. The negative interaction between LINC00565 and KLF9 was responsible for stimulating the malignant development of EC. Knockdown of KLF9 could abolish the regulatory effects of silenced LINC00565 on proliferative ability and tumorigenesis in EC. LINC00565 is upregulated in EC tissues and closely linked to tumor size, pathological staging and poor prognosis in EC patients. LINC00565 stimulates proliferative ability in EC by downregulating KLF9.
Identifiants
pubmed: 32636642
doi: 10.2147/OTT.S249133
pii: 249133
pmc: PMC7334012
doi:
Types de publication
Journal Article
Retracted Publication
Langues
eng
Pagination
6181-6189Commentaires et corrections
Type : RetractionIn
Informations de copyright
© 2020 Yin et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Agric Food Chem. 2020 Jan 8;68(1):213-224
pubmed: 31861958
Onco Targets Ther. 2019 Nov 18;12:9915-9926
pubmed: 31819488
Adv Exp Med Biol. 2017;943:3-46
pubmed: 27910063
Obstet Gynecol. 2012 Aug;120(2 Pt 1):383-97
pubmed: 22825101
Cancer Genet. 2016 Oct;209(10):445-455
pubmed: 27810073
BJOG. 2016 Sep;123 Suppl 3:90-6
pubmed: 27627606
Cancer Res. 2017 Aug 1;77(15):3965-3981
pubmed: 28701486
Front Oncol. 2019 Nov 15;9:1225
pubmed: 31799189
Biomed Pharmacother. 2020 Mar;123:109774
pubmed: 31855739
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S64-S74
pubmed: 30550484
Front Oncol. 2019 Aug 27;9:834
pubmed: 31508377
Gynecol Oncol. 2015 Nov;139(2):261-7
pubmed: 26238457
Genetics. 2019 Dec;213(4):1093-1110
pubmed: 31796550
J Agric Food Chem. 2019 Mar 27;67(12):3341-3353
pubmed: 30835110
PLoS One. 2017 Aug 25;12(8):e0183681
pubmed: 28841682
Adv Exp Med Biol. 2017;1008:283-323
pubmed: 28815544
J Agric Food Chem. 2019 Jul 3;67(26):7378-7389
pubmed: 31184118
Br Poult Sci. 2019 Dec;60(6):790-797
pubmed: 31542936
Int J Gynecol Cancer. 2017 Sep;27(7):1318-1324
pubmed: 29059097
Curr Top Med Chem. 2017;17(15):1750-1757
pubmed: 27848894
Gynecol Oncol. 2017 Apr;145(1):200-207
pubmed: 28040204
Onco Targets Ther. 2019 Sep 24;12:7865-7875
pubmed: 31576144
Am J Cancer Res. 2019 Jul 01;9(7):1367-1381
pubmed: 31392075
Tumour Biol. 2015 Feb;36(2):533-41
pubmed: 25652467
Oncol Lett. 2018 Sep;16(3):3424-3429
pubmed: 30127944
Onco Targets Ther. 2019 Nov 20;12:10011-10022
pubmed: 31819497